Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients

ABSTRACT: Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and TAS 102) no longer have treatment options available while maintaining a good performance status which would allow them to receive a new treatment

DISEASE(S): Colorectal Neoplasms,Metastatic Colorectal Cancer (mcrc)

PROVIDER: 2296303 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR